Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients

Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn and Jeremie Calais
Journal of Nuclear Medicine August 2020, 61 (8) 1171-1177; DOI: https://doi.org/10.2967/jnumed.119.236786
Catherine Meyer
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magnus Dahlbom
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Lindner
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastien Vauclin
4DOSIsoft SA, Cachan, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Mona
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Slavik
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
6Institute of Urologic Oncology, UCLA, Los Angeles, California
7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
8Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
6Institute of Urologic Oncology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 8 1171-1177
DOI 
https://doi.org/10.2967/jnumed.119.236786
PubMed 
31836685

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication September 18, 2019
  • Accepted for publication December 2, 2019
  • Published online August 3, 2020.

Article Versions

  • previous version (December 13, 2019 - 13:35).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Catherine Meyer1,2,
  2. Magnus Dahlbom1,2,
  3. Thomas Lindner3,
  4. Sebastien Vauclin4,
  5. Christine Mona2,
  6. Roger Slavik1,2,5,
  7. Johannes Czernin2,6,7,
  8. Uwe Haberkorn3,7,8 and
  9. Jeremie Calais1,2,5,6
  1. 1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
  2. 2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  3. 3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  4. 4DOSIsoft SA, Cachan, France
  5. 5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
  6. 6Institute of Urologic Oncology, UCLA, Los Angeles, California
  7. 7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
  8. 8Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
  1. For correspondence or reprints contact: Jeremie Calais, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 200 Medical Pl., Suite B114-61, Los Angeles, CA 90095. E-mail: jcalais{at}mednet.ucla.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 61 Citations
  • Google Scholar

Article usage

Article usage: December 2019 to May 2022

AbstractFullPdf
Dec 2019502087
Jan 20203660100
Feb 2020283083
Mar 2020319074
Apr 2020174031
May 2020160047
Jun 2020148080
Jul 20201760133
Aug 2020127851234
Sep 20205064699
Oct 20203393076
Nov 20203423088
Dec 20202812861
Jan 20214495274
Feb 2021181130106
Mar 2021139204188
Apr 2021117176159
May 202183172148
Jun 202192136115
Jul 2021129134101
Aug 202186152137
Sep 2021113190192
Oct 202178180187
Nov 202165152188
Dec 202144190161
Jan 202263139124
Feb 202254127126
Mar 202252151158
Apr 202246133118
May 202276138149
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (8)
Journal of Nuclear Medicine
Vol. 61, Issue 8
August 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1171-1177; DOI: 10.2967/jnumed.119.236786

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1171-1177; DOI: 10.2967/jnumed.119.236786
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
  • FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
  • FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
  • The Latest Developments in Imaging of Fibroblast Activation Protein
  • Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
  • Google Scholar

More in this TOC Section

Theranostics

  • The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
  • A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
  • 89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice
Show more Theranostics

Clinical

  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
Show more Clinical

Similar Articles

Keywords

  • FAPI
  • PET/CT
  • 68Ga
  • dosimetry
  • Biodistribution
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire